Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company” or “Dongyangguang Changjiang Pharmaceutical”, together with its subsidiaries collectively referred to as the “Group”) is a pharmaceutical enterprise focusing on the production, sales and development of pharmaceutical products in the fields of anti-infective, endocrine and metabolic treatments. It is a domestic formulation platform under the Dongyangguang Group. The company entered the Chinese pharmaceutical industry through the company's predecessor, Yichang Changjiang Pharmaceutical Co., Ltd., which was founded in 2001. Up to now, the company has a business history of more than 20 years, and its pharmaceutical sales performance and R&D capabilities rank among the leading positions in the domestic pharmaceutical industry. On May 11, 2015, the Company was restructured as a limited company and successfully listed on the main board of the Hong Kong Stock Exchange Limited (“Stock Exchange”) on December 29, 2015, stock code 01558. Since its establishment, the company has always adhered to the pharmaceutical concept of “serving the Chinese with higher standards”, and has a strong industrial base and leading competitive advantage in pharmaceutical manufacturing and marketing. As of June 30, 2023, the company has a nationwide product distribution network and 1,767 professional sales personnel in China. One of our core products, Colvir (oseltamivir phosphate), is a first-line drug for clinical application against influenza virus in China. Its granular dosage form is our exclusive patented product. Oseltamivir phosphate was included in the “National Essential Drugs Catalogue (2018 Edition)” in 2018. In 2019, our oseltamivir phosphate capsule dosage form was successfully approved and passed the generic drug quality and efficacy consistency evaluation (“consistency evaluation”), making it the first variety in China to meet this standard. In 2020, oseltamivir phosphate continued to be selected for the “Influenza Diagnosis and Treatment Plan (2020 Edition)” issued by the General Office of the National Health Commission. In 2022, our oseltamivir phosphate products continued to be selected in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2022 Edition)” issued by the Ministry of Human Resources and Social Security of China. In addition, the company has established strategic partnerships with many well-known pharmaceutical companies; reached a strategic partnership with Sinopharm Group Yi Pharmaceutical Co., Ltd. (Shenzhen Stock Exchange: 000028.SZ), and the first operation project was officially launched in 2018; a strategic cooperation framework agreement was signed with Kyushu Tong Pharmaceutical Group Co., Ltd. (“Kyushu Connect”). Based on this, the company authorized the relevant specifications of the product Kewei to Jiuzhou Tong's OTC (OTC) channel in mainland China for a period of three years; with the Wuhan Institute of Virology of the Chinese Academy of Sciences and the country The Emergency Prevention and Control Drug Engineering Technology Research Center and Guangdong Dongyangguang Pharmaceutical Co., Ltd. (previously known as Guangdong Dongyangguang Pharmaceutical Co., Ltd., “Guangdong Dongyangguang Pharmaceutical”) signed a letter of intent. Based on this, all parties will jointly establish a national civil-military integration collaborative industrialization platform for emergency prevention and control drugs and a national antiviral drug center. The company believes that the above strategic cooperation relationship will bring ideal development prospects to the company's business. The company has always adhered to the development strategy of specialization, branding and differentiation, and is committed to building the unique brand characteristics and core competitiveness of “Dongyang Changjiang Pharmaceutical” within the industry, creating more value for pharmaceutical consumers and partners. In the future, the company will further enrich its product line, develop markets, improve international production standards and quality of products, continue to expand marketing and sales coverage, promote further growth in the company's business and profitability, and seek higher economic benefits and benefits for investors.
No Data